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Microscopic residual disease is not detectable by current histo-
logical methods and such occult micrometastases represent the
single most important cause of treatment failure in cancer patients
(Deans et al, 1992). Since most circulating tumour cells are
destroyed in the systemic circulation (Tarin et al, 1984; Glaves et
al, 1988), their identification has required the development of
sensitive molecular biology-based methods. The discovery that
many tumours release large amounts of their DNA into the blood
has led to the application of the polymerase chain reaction (PCR)
to the detection of structural abnormalities in tumour cell-derived
DNA in blood (Chen et al, 1996; Nawroz et al, 1996).
Alternatively, reverse transcription PCR (RT-PCR) has been used
to detect tumour tissue-specific gene expression (Johnson et al,
1995). Although such advances appear to have resulted in the
molecular detection of systemic tumour cells in patients with
many different cancers, the relationship between circulating cells
and ultimate prognosis is still unclear (reviewed in Bustin and
Dorudi, 1998).
Colorectal cancer lacks a tumour-specific marker and several
mRNAs, including carcinoembryonic antigen (Gerhard et al,
1994; Mori et al, 1995; Jonas et al, 1996; Liefers et al, 1998), the
lymphatic homing receptor CD44 (Wong et al, 1997) and various
cytokeratins (Burchill et al, 1995; Gunn et al, 1996; Denis et al,
1997), have been evaluated as potential markers of occult blood,
lymph node and/or bone marrow metastasis. Expression of cytok-
eratin 19 (ck19; Genbank accession no Y00503) has been reported
in a wide range of tissues (Quinlan et al, 1985) including normal
lymph nodes, bone marrow and peripheral blood (Burchill et al,
1995; Gunn et al, 1996). Expression of cytokeratin 20 (ck20;
Genbank accession no X73501), detected in most colorectal
cancers and their metastases (Moll et al, 1992), initially appeared
to be more limited (Moll et al, 1993) and its detection by RT-PCR
has been used to identify occult metastases in colorectal cancer
patients (Denis et al, 1997; Funaki et al, 1997; Dorudi et al, 1998).
However, ck20 mRNA transcription (Denis et al, 1997) as well as
protein expression (Litle et al, 1997) has been described recently
in the blood of healthy controls, making its use in the detection
of micrometastatic cells questionable (Wyld et al, 1998). Most
recently, expression of guanylyl cyclase C (GCC; Genbank acces-
sion no U20230/S57551), which specifies the guanylate cyclase-
coupled enterotoxin receptor, has been proposed as a selective
marker for metastatic colorectal tumours in extra-intestinal tissues
(Carrithers et al, 1996; Waldman et al, 1998).
We have used the fluorogenic 5¢-nuclease (Taqman) assay
(Holland et al, 1991) which, with appropriate instrumentation,
allows full quantitation and analysis of the PCR reaction, to inves-
tigate the relevance of detecting ck19 and ck20 as well as GCC in
the peripheral blood of patients with colorectal cancer. T7 poly-
merase-transcribed templates specific to each marker were used to
generate standard curves that allowed absolute quantitation of
mRNA copy numbers. Our results reveal that ck19/20 expression
occurs too frequently in the peripheral blood of healthy volunteers
to be clinically useful in the assessment of colorectal cancer
patients. The biological significance of detection of GCC tran-
scription awaits complete validation in further longitudinal
studies.
MATERIALS AND METHODS
Patients
This study was approved by the Local Research Ethics Committee
of the East London and City Health Authority. Venous blood
samples were obtained from 27 patients with colorectal cancer
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Correspondence to: SA Bustin(age 39–80 years) at the time of operation. A second sample was
obtained from 15/27 patients at the time of their 1-month follow-
up visits. Patient data are summarized in Table 1. In each case 3-ml
samples of peripheral blood were obtained and stored in sterile
lithium heparin vacutainers for a maximum of 2 h before RNA
was extracted. In our hands use of heparinized containers,
combined with the RNA extraction protocol detailed below, did
not inhibit the subsequent RT-PCR reaction. Blood samples were
taken from 21 healthy control subjects (age 26–61 years).
Additional samples were taken from 14/21 at weekly intervals for
3 weeks.
Tumours
To confirm expression of the three potential marker genes in
colorectal tumours, two separate areas from each of five tumours
(four patients, two synchronous tumours) were removed, washed
in distilled water, blotted dry and weighed.
RNA extraction
All RNA extractions were carried out in a separate room in a class
2 containment hood using dedicated pipettes with aerosol-resistant
tips (Gilson). For each 3-ml blood sample, total RNA was
extracted in 2 ´ 1.5 ml aliquots using the RNeasy Blood Mini Kit
(Qiagen Ltd, Crawley, UK). Manufacturer’s instructions were
followed except that following lysis of red blood cells, leucocytes
were given two additional washes with 3-ml EL (Qiagen Ltd)
buffer. This was to ensure complete removal of any potential
RT-PCR inhibitors. RNA was eluted in distilled DEPC-treated
water, the two aliquots were combined and stored at – 70°C at a
concentration of 75 ng ml. RNeasy Mini Kits (Qiagen Ltd) were
also used to extract approximately 25 mg of total RNA from 106
T84 cells, a human colorectal cancer cell line. This RNA was
stored at – 70°C at a concentration of 50 ng ml. RNA from tumour
tissue was extracted using RNeasy Mini kits (Qiagen, Crawley,
UK) according to manufacturer’s instructions and stored at – 70°C
at a concentration of 50 ng ml. All quantitation was carried out
using a Hitachi U-3000 spectrophotometer.
Primers and probes
All probes were labelled with a fluorescent dye (6-carboxy-
fluorescein, FAM) and a quencher (6-carboxy-tertramethyl-
rhodamine, TAMRA) and were purchased, together with their
respective primer sets from PE Applied Biosystems, Warrington,
UK. Cytokeratin primers and probes were designed using Primer
Express software (PE-ABI) with manual fine-tuning. The ck20
primers bind to sequences in ck20 exons 1 and 2, generating an
amplicon of 86 bp, with the probe hybridizing to both exons
(Figure 1A). The ck19 primers bind to sequences in exons 2 and 3,
generating an amplicon of 75 bp, with the probe binding to both
exons (Figure 1B). Two design features minimize amplification
and detection of the ck19 pseudogene (Genbank accession no
M33101). The downstream primer contains two mismatches with
the ck19 pseudogene and the probe contains a further three
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Table 1 Clinical and biological status of patients with colorectal carcinoma
GCC
Patient Sex/age Duke’s stage ck19 ck20 Peri-operative 1 month post-operative
527 F/66 B – + – –
528 M/47 C2 + + + +
529 F/75 D – + + +
530 F/73 C2 – + – +
531 F/78 B – + + +
532 M/75 D – + – –
533 M/67 B – + + +
534 M/61 B + + + +
536 M/62 C + + – –
537 M/56 D – + – +
538 M/66 B – + – –
539 M/71 D – + – –
541 M/49 D – + + +
542 F/39 C + + + +
543 F/80 B – + + +
544 F/43 B+Ca –++ +
545 M/39 A – + + +
546 M/75 B + + + +
547 M/67 B + + + +
548 M/69 D – + + +
549 F/62 B + + + +
550 M/62 C – + + +
551 F/68 B – + + +
552 F/84 B – + + +
553 F/55 A – + + +
554 F/44 B – + + +
555 F/76 B – + + +
aSynchronous tumour.mismatches. Since the probe is blocked at its 3¢-end by the
quencher, it cannot be extended and stabilized during the PCR,
making it less likely to remain hybridized to the pseudogene. The
forward GCC primer binds to sequences in exons 1 and 2 and, with
the downstream primer, generates an amplicon of 86 bp (Figure
1C). The glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
Genbank accession no J04038) probe/primer set spans introns 2
and 3, generates an amplicon of 226 bp and the probe binds to
exon 3. It is identical to the PE-ABI set (402869), except that the
probe was synthesized with the same reporter dye (FAM) as the
cytokeratin probes. All primer/probe sequences are detailed in
Table 2.
RT-PCR reactions
The one-tube/one enzyme RT-PCR protocol was consistently more
sensitive in our hands than separate reverse transcription followed
by PCR (Dorudi et al, 1998), and we therefore used this protocol
with all 5¢-nuclease assays. The volume of each reaction was
25 ml, allowing us to analyse each sample five times. Since each
RT-PCR reaction was carried out in duplicate, this resulted in ten
quantitations per RT-PCR sample. To prevent carry-over of conta-
minating amplified DNA, the reaction was carried out in the
presence of dUTP. Prior to RT, the RNA template was heated for
2 min at 50°C in the presence of 0.01 U l-1 uracil N-glycosylase.
Following 30 min RT at 60°C and 5 min denaturation at 92°C,
PCR was carried out for 40 cycles of 20 s at 92°C and 30 s at 60°C
in the presence of an oligonucleotide probe containing a fluores-
cent reporter at its 5¢-end and a quencher at its 3¢-end. Following
target amplification, the probe anneals to the amplicon and is
displaced and cleaved between the reporter and quencher dyes by
the nucleolytic activity of the polymerase. The amount of product
resulting in detectable fluorescence at any given cycle within the
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Figure 1 Location of cytokeratin and GCC primers and probes. E1, E2, E3
designate exons, ck20F, ck19F, GCCF and ck20R, ck19R, GCCR designate
forward and reverse primers, respectively, and ck20P, ck19P, GCCP
designate the hybridization probe that has the reporter (R) at its 3¢-end and
the quencher (Q) at its 5¢-end
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Figure 2 Standard curves of RT-PCR amplification of GAPDH, ck19, ck20
and GCC amplications. The log starting copy number is plotted against the
threshold cycle Ct. Error bars indicate standard deviationsexponential phase of PCR is proportional to the initial number of
template copies. The number of PCR cycles (threshold cycle, Ct)
needed to detect the amplicon is therefore a direct measure of
template concentration. Two no-template controls were included
with every amplification run; one was prepared prior to opening
all the tubes and dispensing the various reagents, the other at the
end of the experiment. This allowed us to monitor any contamina-
tion arising during the handling of the reagents. Reactions were
recorded and analysed using the ABI 7700 Prism Sequence detec-
tion system (Perkin-Elmer Applied Biosystems, Warrington, UK).
Generation of standard curves
Accurate quantitation of each potential marker requires that the
absolute quantities of each transcript are known. Amplicons speci-
fying GAPDH, ck19, ck20 and GCC were amplified from T84
mRNA using the appropriate primers and cloned behind the T7
RNA polymerase promoter in the pCR2.1 TA-cloning vector
(Invitrogen, Leek, The Netherlands). After linearization of the
plasmid, RNAs were transcribed using T7 RNA polymerase
(Promega) to generate transcripts of 235, 195, 184 and 195 b
respectively. Contaminating DNA was removed by DNAse diges-
tion (Boehringer Mannheim). RNAs were purified using a cleanup
kit (Qiagen) and quantitated on a Genequant spectrophotometer
(Pharmacia, St Albans). A total of 1 mg of an average 1000 b
mRNA contains 1.9 ´ 1012 molecules. Serial dilutions of the T7
transcripts were carried out in duplicate from 1 ´ 109 molecules
down to ten molecules and used in RT-PCR reactions. Reactions
were carried out four times, each one in triplicate. By plotting the
log [calculated copy number] against the threshold cycle, a stan-
dard curve was obtained for each amplicon. The copy numbers (N)
of unknown samples were calculated from the regression lines
according to the formula: N = Ct — b/m, where Ct is the threshold
cycle, b is the y-intercept and m is the slope of the standard curve
lines.
RESULTS
Standard curves
The standard curves in Figure 2 show consistent amplification
over seven orders of magnitude for all four targets, resulting in the
detection of fewer than 100 copies of mRNA for ck19/20 and
GCC. The minimum number of GAPDH mRNA molecules
detected was 400. Differences are likely to be caused by differing
amplification efficiencies of the four amplicons. The GCC
primer/probe combination consistently gave the highest levels of
sensitivity, followed by ck19 and 20.
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Table 2 Primer and probe sequences
Primer/probe sets Amplification Primers Probe (5´FAM-3´TAMRA)
Forward:
GCGACTACAGTGCATATTACAGACAA
ck20 exons 1 and 2 Reverse: TGAGCATCCTTAATCTGACTTCGCAGCTCTTC
GCAGGACACACCGAGCATTT
Forward:
TCGACAACGCCCGTCTG CCGAACCAAGTttGAGACGGAaCAGG
ck19 exons 2 and 3 Reverse:
CcaCGCTCATGCGCAG
Forward:
ACGTCTGCAAAATGCTGGC
GCC exons 1 and 2 Reverse: AGACCATCCGAATACATGAAAGTAGCGTTCACAG
GGCAGTCGCCTGAGTTATGAA
Forward:
GAAGGTGAAGGTCGGAGTC
GAPDH exons 2 and 3 Reverse: CAAGCTTCCCGTTCTCAGCC
GAAGATGGTGATGGGATTTC
Oligonucleotide sequences are described in the 5’–3’-direction. Mismatches between ck19 and its pseudogene in the reverse primer and the probe are
indicated by the use of lower case letters.
Table 3 Expression of marker genes in blood, colorectal tumour tissue and tissue culture cells
Marker Control blooda Patient blooda Tumourb T84 cellc
GAPDH ± SD 4.4 ´ 109 ± 3 ´ 109 5.8 ´ 109 ± 7.7 ´ 109 8.3 ´ 104 ± 1 ´ 106 1.2 ´ 105 ± 1.4 ´ 104
ck19 ± SD 2 ´ 104 ± 3.2 ´ 105 9.4 ´ 103 ± 2.2 ´ 104 7.1 ´ 104 ± 1.8 ´ 105 8.2 ´ 103 ± 6.7 ´ 103
ck20 ± SD 6.8 ´ 103 ± 1.7 ´ 105 2.9 ´ 103 ± 1.9 ´ 105 3.2 ´ 104 ± 8.2 ´ 105 1 ´ 104 ± 1.6 ´ 103
GCC ± SD 0 ± 1.6 ´ 104d 4.6 ´ 102 ± 1.1 ´ 107e 2.2 ´ 103 ± 8.1 ´ 103 2.5 ´ 102 ± 7.9 ´ 101
The median mRNA copy numbers are expressed aper ml of blood, bper mg of tissue or cper cell. The median number of nucleated blood cells (NBC) in individual
blood samples was 3.4 ´ 106 ± 1.7 ´ 106. dThe large standard deviation is due to the one healthy volunteer expressing high copy numbers of GCC. eThe large
standard deviation is due to one patient expressing 7 ´ 107 copies of GCC per ml blood. Without that patient, the standard deviation would be 8.2 ´ 102.ck19/20 and GCC expression in tumour tissue
To quantitate transcription levels in colon epithelial cells, RNA
was prepared from five tumours, two of which were synchronous.
mRNA for all three markers was detected and median expression
levels are shown in Table 3. However, mRNA copy numbers
differed widely between different tumours, ranging 4.9 ´ 103 to
4.5  ´ 105, 6.1 ´ 101 to 2.3 ´ 106 and 4.6 ´ 101 to 1.9 ´ 104
respectively for ck19, ck20 and GCC (Figure 3). There was little
variation between different sections of the same tumour (results
not shown).
ck19/20 and GCC expression in blood from healthy
volunteers
All 21 healthy controls expressed ck20 and six expressed ck19
mRNA. Again there was significant variation in mRNA copy
numbers, which ranged 8.4 ´ 105 to 7.3 ´ 106 and 3.8 ´ 102 to 8.8
´ 105 for ck19 and ck20. Similar variation was also observed in
blood samples taken from the same 14 individuals over a 3-week
period. Transcription of GCC mRNA was detected in one healthy
control. This was confirmed in two additional samples taken at
weekly intervals. All three samples also had high levels of ck19
and ck20 mRNA. The copy number of the housekeeping gene
GAPDH also showed significant variation, ranging 2 ´ 102 to
6.5 ´ 103 copies per nucleated blood cell. Median expression levels
are shown in Table 3.
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Figure 3 Scatterplot showing the variation in mRNA transcription (plotted
as log copy numbers) between five tumours. Copy numbers are expressed
per mg of wet tissue. A comparison within each of the five tumours showed
very little variation
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Figure 4 Lack of correlation between mRNA copy numbers and disease
stage in peri-operative peripheral blood samples. The range of mRNA copy
numbers obtained with peripheral blood samples from healthy volunteers
shows no difference compared with the range obtained in colorectal cancer
patients. The scatter chart plots log copy number per ml blood. Similar
results were obtained when the copy numbers per cell were plotted. (A)
ck20; (B) GCC. Twenty of the controls and four of the Duke’s D patients did
not have detectable GCC expression
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Figure 5 Post-operative expression of ck20 and GCC in peripheral blood of
colorectal cancer patients. The plots track changes in the log copy numbers
seen from the time of operation. (A) ck20; (B) GCC. u- - - -  Duke’s B,
s- - - - Duke’s C, n—Duke’s D
1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
Controls
n = 21
A
n = 2
B
n = 13
C
n = 5
D
n = 7ck19/20 and GCC expression in blood from colorectal
cancer patients
ck20 mRNA could be detected in all 27 peri-operative blood
samples. Median expression levels are shown in Table 3. There
was no significant difference in ck20 copy numbers compared to
those obtained in healthy controls. There was also no difference
between patients with different stages of colorectal cancer (Figure
4). ck19 mRNA was detected in seven blood samples, but there
was no correlation with ck20 expression levels. GCC mRNA was
detected in 20/27 samples, but 4/7 samples from Duke’s D patients
were GCC-negative.
One to 2 months post-operatively, expression of all ck20
mRNAs was still apparent at levels similar to those detected in
peri-operative samples (Figure 5A). GCC expression was detected
in an additional two patients (one Duke’s C2, one Duke’s D).
Interestingly, all of the patients that were GCC-positive at the time
of operation remained so (Figure 5B).
Comparison of mRNA copy numbers between tissue
culture cells and nucleated blood cells
We used several preparations of T84 mRNA to determine the copy
numbers of GAPDH, ck19/20 and GCC in this colorectal cancer
tissue cell line. In contrast to the results obtained in vivo, there was
significantly less variation in copy numbers (Table 3). However,
GAPDH copy numbers per cell were two orders of magnitude
greater than those calculated per nucleated blood cell (1.9 ´ 103 ±
1.2 ´ 103). This is relevant, since blood spiking experiments with
tissue culture cells are generally used to assess the sensitivity of
the RT-PCR reaction. This result suggests that sensitivity levels
obtained this way must be treated with caution.
DISCUSSION
Although RT-PCR is widely used to identify mRNA presumed to
originate from circulating viable tumour, the clinical significance
of their detection remains unknown (Bustin and Dorudi, 1998).
There are several problems associated with its use as a routine tool
in clinical medicine. Standardization of the technique across
laboratories and questions concerning sensitivity and specificity
are vital issues, which can hinder the translation of results into
clinical practice. This is highlighted by our finding that mRNA
copy numbers in T84 cells are two orders of magnitude greater
than in vivo. Since all previous reports base their claimed sensi-
tivity on spiking experiments that use tissue culture cells, our
results suggest that their use overestimates the sensitivity of the
RT-PCR assay. The difficulty in obtaining quantitative information
has limited the prognostic power of the RT-PCR and, although
several methods have been devised to attempt better quantitation
(Fukuhara et al, 1992; Hayashi et al, 1995; Leygue et al, 1996),
none are easily translated into routine use.
Paradoxically, as protocols have become more refined and
detection limits have been reduced, several reports have suggested
that tissue-specific genes may be ‘illegitimately’ transcribed in
non-specific cells. Illegitimate transcription was originally defined
as the low-level transcription of any gene in any cell and was
proposed to account for the detection of mRNA transcripts of
several tissue-specific genes in human non-specific cells (Chelly
et al, 1989; Berg et al, 1990). Transcription is initiated from the
normal promoter (Chelly et al, 1991) and, although the effect has
been validated for a large number of mRNAs (Cooper et al, 1994),
it is not observed for every mRNA (Sorg et al, 1991). There are
conflicting reports both as to whether illegitimate transcription
of cytokeratins contributes to the detection of false positives
(Burchill et al, 1995; Foss et al, 1995; Denis et al, 1997;
Dingemans et al, 1997; Hanekom et al, 1997; Zippelius et al,
1997) and which cytokeratins are affected (Traweek et al, 1993).
Our results shed some light on this. They confirm previous
reports suggesting that haematopoietic cells extracted from
healthy volunteers express both ck19 (Burchill et al, 1995) and
ck20 mRNA (Denis et al, 1997). Our results differ, in that tran-
scription of ck20 mRNA was detected in all 21 healthy control
samples analysed, whereas transcription of the ck19 gene could be
detected in only 30% of healthy controls. Expression levels of both
are sufficient to generate false positive results and strongly suggest
that their usefulness in the detection of micrometastatic tumour
cells by conventional RT-PCR is limited. Of course, ck19/20 tran-
scripts may originate from non-tumour epithelial cells present in
the circulation and the sporadic nature of their presence may
account for the differing levels of transcription we have detected.
The ability to quantitate expression levels should permit a more
accurate assessment of transcription above background levels.
We have detected GCC mRNA in only one normal healthy
control so far. This was confirmed in two further samples, taken at
1-week intervals. GCC copy numbers in these samples were
higher than copy numbers in 26/27 of the patients. Interestingly,
these samples also contained very high copy numbers of both ck19
and 20 mRNA. The meaning of these results remains unknown
and may reflect unusually high levels of illegitimate transcription
for all three genes in that person, or it could indicate the presence
of epithelial cells in the peripheral blood.
To determine whether quantitative RT-PCR can overcome the
problems associated with either illegitimate transcription or the
presence of epithelial cells in the blood, and to ascertain whether
detection of ck19/ck20 and GCC mRNA might correlate with
disease stage, we applied our protocol to the screening of blood
from patients undergoing surgery for colorectal cancer. As is
evident from Figure 4A, their pre-operative blood samples showed
no significant difference in the levels of ck20 mRNA compared
with healthy control subjects, and the same was true for ck19.
There also appeared to be no difference in ck19/20 copy numbers
between patients with lymph node-negative tumours, those with
Duke’s stage C and those with confirmed distant metastatic spread
to the liver. Figure 5A shows that the same is true after 1 month’s
follow-up. This is in agreement with a recent report which
suggests that there is no correlation between the detection of ck20
mRNA in the peripheral blood and disease progression (Wyld
et al, 1998). Expression of GCC, on the other hand, which had
been undetectable in 20/21 controls, was identified in 20/27
pre-operative samples (Figure 4B). Since GCC is a tissue-specific,
not a tumour-specific, marker this suggests that the RT-PCR is
detecting the presence of colon epithelial cells in patients’ blood.
There was no correlation between disease stage and GCC copy
number in pre-operative blood samples, in contrast to a previous
report that suggests GCC transcription can be detected only in the
peripheral blood of Duke’s C and D patients (Carrithers et al,
1996). Our data also suggest that all patients that tested positive
for GCC expression in their peri-operative samples still have colon
epithelial cells circulating in their blood 1 month after surgery and
identify two patients (one Duke’s C2, one Duke’s D) in whose
blood GCC expression can now be detected (Figure 5B).
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that healthy volunteers express both ck19 and ck20 mRNA in their
peripheral blood. This raises serious doubt about their usefulness
in colorectal cancer. This doubt is reinforced by the significant
variation in their copy numbers. We have been unable to show a
correlation between ck19 and ck20 transcription and disease stage
in peri-operative peripheral blood samples of colorectal cancer
patients. One to 2 months after surgery, there are still epithelial
cells detectable in blood samples from every patient, regardless of
Duke’s stage. The same is true for the 74% of patients that showed
expression of GCC in their peri-operative blood samples. The
ability to quantitate is invaluable in distinguishing background
levels of transcription and it will be crucial to validate this tech-
nique in prospective studies. Finally, it must always be remem-
bered that, by themselves, such novel techniques will not translate
into improved patient outcome unless corresponding advances are
made in adjuvant treatment modalities.
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